Dr Reddy’s Laboratories is positioning itself for a protracted-time period strategy in weight problems and metabolic therapies, creating a broader GLP-1 pipeline and constructing a help ecosystem even because it prepares for a Day 1 launch of generic semaglutide in India. The corporate indicated that past the rapid semaglutide alternative, it has a number of GLP-1 belongings underneath growth and is exploring improvements, together with potential drug-system combos.
“Making certain that we’ve got the merchandise that matter now and are anticipated to be the future normal of care, we’ve got them in our R&D pipeline,” M V Ramana, CEO – Branded Markets (India & Rising Markets), Dr Reddy’s Laboratories, informed Enterprise Right now.
Alongside product growth, the firm is investing in market groundwork. Ramana stated inner assessments have been performed to know gaps at each physician and affected person ranges earlier than finalising the strategy. These included figuring out consciousness gaps amongst physicians, challenges sufferers face throughout remedy, points round dose titration and unwanted side effects, and what occurs when sufferers plateau throughout remedy. “The product alone isn’t the solely want,” he stated.
To handle these gaps, Dr Reddy’s is working with the Worldwide Weight problems Societies and plans to determine Weight problems Centres of Excellence throughout India. These centres will give attention to physician schooling, proof technology, and structured affected person administration. The corporate can be creating diet merchandise tailor-made for GLP-1 customers. “We’re going past the capsule,” Ramana stated, including that the method contains affected person onboarding, dose titration steerage and dietary help.
The broader strategy comes as competitors intensifies forward of semaglutide’s patent expiry in March. The corporate has acquired regulatory approval in India and plans to launch the product instantly after expiry. “We might be launching the product on day one in India,” Ramana stated.
Semaglutide, a GLP-1 receptor agonist used for the remedy of kind 2 diabetes and weight problems, has grow to be one in all the world’s greatest-promoting metabolic therapies. Offered globally by Novo Nordisk underneath manufacturers equivalent to Ozempic and Wegovy, the drug has generated billions of {dollars} in annual income.
The launch comes as India’s diabetes medicine market is estimated at round $1.7 billion (roughly ₹14,000 crore) in 2024 and is predicted to develop over the subsequent 5 years, in keeping with Mordor Intelligence. In keeping with the newest Nationwide Household Well being Survey (NFHS-5), practically one in 4 Indian adults is chubby or overweight.
With patent expiry, a number of home producers are making ready to enter what may grow to be one in all the best remedy segments in the nation. Solar Pharma has indicated it’s going to introduce its generic semaglutide underneath the model names Noveltreat for power weight administration and Sematrinity for diabetes following patent expiry and regulatory clearances.
Alkem Laboratories and Zydus Lifesciences have additionally secured approvals for generic semaglutide formulations and are anticipated to launch merchandise. Firms equivalent to Biocon and Cipla have indicated that they’re evaluating launch and pricing methods in the section.
Whereas pricing stress is anticipated, Ramana stated differentiation will come from product confidence and physician engagement. “Firms which have confidence in the product that they’ve developed with the proper medical trials and all the assessments which might be required to provide the confidence to the physician, and corporations which have subject forces which have the confidence of the medical doctors would acquire on this section,” he stated.
“In the case of diabetes, there isn’t a hypoglycaemic impact. There’s a good discount of HbA1c, and it additionally has the benefit of weight administration and organ safety,” Ramana stated. He famous that round 590 million individuals globally reside with diabetes, together with roughly 100 million in India and about 135 million pre-diabetic sufferers. Globally, weight problems impacts practically 1.5 billion individuals.
On pricing, Ramana indicated that the Indian market would stay aggressive. “If it isn’t aggressive, and being an out-of-pocket product, then the utilization of the product wouldn’t be as a lot,” he stated, noting that backward integration into API and formulation offers price flexibility.
Business observers anticipate costs to average as soon as generics enter, doubtlessly increasing entry in India’s largely out-of-pocket healthcare system. Sheetal Sapale, Vice President, Business, Pharmarack, stated generic entry usually results in sharp worth erosion in India. “Often, costs come down to 1-third to 1-fifth of the innovator product. Month-to-month volumes enhance three to 5 occasions for the first 5 to 6 months after which stabilise,” she stated.
Ramana additional stated that globally, filings are underway in rising markets and Canada, with bigger markets equivalent to the US and Europe anticipated to open later. “Over the subsequent two years, markets will open up primarily based on the velocity at which the regulator can have a look at the dossiers,” he stated.
Whereas the firm declined to supply income projections, Ramana described semaglutide as an vital product inside its broader progress framework that features base enterprise enlargement, price optimisation, pipeline growth and enterprise growth. As the GLP-1 area turns into extra crowded, innovation is predicted to proceed round dosing frequency, oral options and facet-impact profiles, he stated.
Source link
#Reddys #plans #capsule #strategy #Semaglutide #BusinessToday
